We use cookies on your browser to customize content for your viewing and for analytics. If you click “Accept” or continue to browse our website, we assume you have agreed to our use of cookies. For details, please refer to our Cookies Policy.
12 August
229
Pulnovo Medical Limited,a globally recognized device pioneer in the treatment of Pulmonary Hypertension (PH) and Heart Failure (HF), is pleased to announce the successful enrollment of the first patient in Malaysia for the international multi-center clinical study of Percutaneous Pulmonary Artery Denervation (PADN) for treating PH associated with left heart disease. This marks significant progress in the PADN global clinical research initiative in Asia and advances the development of PADN's globalization strategy within the Asia-Pacific region.
During this operation, the team of Dr.ong Tiong kiam, the director of Sarawak Heart Center,Dr. Alan Fong,the chairman of National Cardiovascular Society ,Dr.Koh Keng Tat and Dr.Oon Yen Yee successfully performed the PADN procedure . The entire process went smoothly, with the PADN technology demonstrating excellent performance, effectively complementing the medical team’s expertise. This success once again underscores the safety and effectiveness of PADN technology, earning high praise from the Malaysian medical community, particularly the teams led by Dr. Ong Tiong Kiam and Dr. Alan Fong.
The successful completion of this clinical procedure has also reinforced the positive trend observed in clinical data, showcasing the seamless integration of PADN technology with the latest innovations. Post-enrollment, clinical parameters indicated strong outcomes, with significant improvements in patient data. This achievement sets a new milestone for the global expansion and application of PADN technology.
From Singapore to Malaysia, PADN technology has gradually established its presence in key heart centers across the Asia-Pacific region. With the approval in China and the rapid development of clinical trials in Europe and the United States, Pulnovo Medical continues to bring PADN technology to the global stage, igniting enthusiasm among international medical professionals. Looking ahead, Pulnovo Medical remains committed to promoting technological innovation and maintaining originality from a global perspective to advance healthcare worldwide.
About PADN
Pulmonary Artery Denervation (PADN) is a percutaneous pulmonary artery intervention procedure that uses a PADN catheter to deliver radiofrequency energy to the sympathetic nerves in the outer membrane of the pulmonary artery, resulting in the disappearance of the myelin sheath of the nerves and the fusion of the axons, which inhibits sympathetic activity, increases cardiac output, reduces pulmonary artery pressure , inhibits the pathologic remodeling of the pulmonary arteries, improves the patient's exercise endurance and cardiac function, and achieves long-term benefits from a single minimally invasive procedure.
About Pulnovo Medical
Pulnovo Medical Limited, is a globally recognized device pioneer in the treatment for pulmonary hypertension and heart failure. Established in 2013 and rooted in innovation, Pulnovo Medical is committed to leveraging our deep expertise in the science of breakthrough technologie with the goal to market our innovative therapeutic solutions and benefit patients around the world.